share_log

Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate

Benzinga ·  May 8 07:38

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $33.126 million which missed the analyst consensus estimate of $34.473 million by 3.91 percent. This is a 14.40 percent decrease over sales of $38.698 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment